New markers for minimal residual disease detection in acute lymphoblastic leukemia
Elaine Coustan-Smith1, Guangchun Song, Christopher Clark
1Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA.
Abstract:
To identify new markers for minimal residual disease (MRD) detection in acute lymphoblastic leukemia (ALL), we compared genome-wide gene expression of lymphoblasts from 270 patients with newly diagnosed childhood ALL to that of normal CD19⁺CD10⁺ B-cell progenitors (n = 4). Expression of 30 genes differentially expressed by ≥ 3-fold in at least 25% of cases of ALL (or 40% of ALL subtypes) was tested by flow cytometry in 200 B-lineage ALL and 61 nonleukemic BM samples, including samples containing hematogones. Of the 30 markers, 22 (CD44, BCL2, HSPB1, CD73, CD24, CD123, CD72, CD86, CD200, CD79b, CD164, CD304, CD97, CD102, CD99, CD300a, CD130, PBX1, CTNNA1, ITGB7, CD69, CD49f) were differentially expressed in up to 81.4% of ALL cases; expression of some markers was associated with the presence of genetic abnormalities. Results of MRD detection by flow cytometry with these markers correlated well with those of molecular testing (52 follow-up samples from 18 patients); sequential studies during treatment and diagnosis-relapse comparisons documented their stability. When incorporated in 6-marker combinations, the new markers afforded the detection of 1 leukemic cell among 10(5) BM cells. These new markers should allow MRD studies in all B-lineage ALL patients, and substantially improve their sensitivity.
Insights
New flow cytometry markers improve minimal residual disease detection in childhood acute lymphoblastic leukemia (ALL). These markers enhance sensitivity for detecting leukemia cells, aiding in treatment monitoring for ALL patients.
Area of Science:
- Hematology
- Immunology
- Molecular Biology
Background:
- Minimal residual disease (MRD) detection is crucial for acute lymphoblastic leukemia (ALL) treatment.
- Current MRD detection methods have limitations in sensitivity and applicability across all B-lineage ALL subtypes.
Purpose of the Study:
- To identify novel, reliable markers for MRD detection in childhood ALL.
- To improve the sensitivity and scope of MRD assessment in B-lineage ALL.
Main Methods:
- Genome-wide gene expression profiling of lymphoblasts from 270 newly diagnosed childhood ALL patients compared to normal B-cell progenitors.
- Flow cytometry validation of 30 differentially expressed genes in 200 B-lineage ALL and 61 nonleukemic bone marrow samples.
- Correlation of flow cytometry MRD detection with molecular testing and assessment of marker stability during treatment.
Main Results:
- 22 novel markers (e.g., CD44, BCL2, CD73) were identified with differential expression in up to 81.4% of ALL cases.
- Marker expression showed association with specific genetic abnormalities in ALL.
- Flow cytometry using these markers demonstrated high concordance with molecular MRD testing and stable expression over time.
- 6-marker combinations achieved detection of 1 leukemic cell per 10^5 bone marrow cells.
Conclusions:
- The identified markers significantly enhance MRD detection capabilities in B-lineage ALL.
- These markers offer improved sensitivity and broader applicability for MRD monitoring in ALL patients.
- The findings pave the way for more precise and effective treatment strategies in childhood ALL.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016